دورية أكاديمية
Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT)
| العنوان: | Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT) |
|---|---|
| المؤلفون: | Gómez-Seguí, Inés, Francés Aracil, E., Mingot-Castellano, María Eva, Vara Pampliega, M., Goterris Viciedo, R., García-Candel, Faustino, Pascual-Izquierdo, Cristina, Río-Garma, Julio del, Guerra Domínguez, L., Vicuña Andrés, I., García-Arroba Peinado, José, Zalba, Saioa, Vidan Estévez, J. M., González Arias, E., Campuzano Saavedra, V., García Gala, J. M., Ortega Sánchez, S., Martínez Nieto, J., Pardo Gambarte, L., Solé Rodríguez, M., Fernández-Docampo, M., Ávila Idrovo, L. F., Hernández, L., Cid, Joan, Rubia, Javier de la, from the Spanish TTP Registry (REPTT, Registro Español de la Purpura Trombocitopénica Trombótica) |
| بيانات النشر: | John Wiley & Sons |
| سنة النشر: | 2023 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| مصطلحات موضوعية: | Aged, Caplacizumab, Rituximab, Thrombotic thrombocytopenic purpura |
| الوصف: | Immune thrombotic thrombocytopenic purpura (iTTP) is an ultra-rare disease that seldom occurs in the elderly. Few reports have studied the clinical course of iTTP in older patients. In this study, we have analysed the clinical characteristics at presentation and response to therapy in a series of 44 patients with iTTP ≥60 years at diagnosis from the Spanish TTP Registry and compared them with 209 patients with <60 years at diagnosis from the same Registry. Similar symptoms and laboratory results were described in both groups, except for a higher incidence of renal dysfunction among older patients (23% vs. 43.1%; p = 0.008). Front-line treatment in patients ≥60 years was like that administered in younger patients. Also, no evidence of a difference in clinical response and overall survival was seen in both groups. Of note, 14 and 25 patients ≥60 years received treatment with caplacizumab and rituximab, respectively, showing a favourable safety and efficacy profile, like that observed in patients <60 years. ; Peer reviewed |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0007-1048 1365-2141 |
| العلاقة: | The underlying dataset has been published as supplementary material of the article in the publisher platform at https://doi.org/10.1111/bjh.19109Test; https://doi.org/10.1111/bjh.19109Test; Sí; British Journal of Haematology 203(5): 860-871 (2023); http://hdl.handle.net/10261/350868Test |
| DOI: | 10.1111/bjh.19109 |
| الإتاحة: | https://doi.org/10.1111/bjh.19109Test http://hdl.handle.net/10261/350868Test |
| حقوق: | none |
| رقم الانضمام: | edsbas.CB9E3F0C |
| قاعدة البيانات: | BASE |
| تدمد: | 00071048 13652141 |
|---|---|
| DOI: | 10.1111/bjh.19109 |